Search
regorafenib (BAY 73-4506, Stivarga)
Indications:
- metastatic colorectal carcinoma
- if previously treated with fluoropyrimidine-, oxaliplatin-, & irinotecan-based chemotherapy, with an anti-VEGF therapy, &, if KRAS wild type, with an anti-EGFR therapy [2]
- advanced gastrointestinal stromal tumors [3]
Dosage:
Storage:
- store in orginal container
- must be protected from moisture
- original container has a desiccant
- must be used within 28 days once original container is opened [4]
Mechanism of action:
- receptor tyrosine kinase inhibitor
Interactions
drug adverse effects of tyrosine kinase inhibitor(s)
General
small inhibitory antineoplastic agent (ib drug)
antineoplastic tyrosine kinase inhibitor
Database Correlations
PUBCHEM correlations
References
- Wikipedia: Regorafenib
http://en.wikipedia.org/wiki/Regorafenib
- FDA Approval for Regorafenib
National Cancer Institute
http://www.cancer.gov/cancertopics/druginfo/fda-regorafenib
- FDA News Release: Feb. 25, 2013
FDA approves Stivarga for advanced gastrointestinal stromal tumors
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm340958.htm
- Prescriber's Letter 21(6): 2014
Oral Meds to Keep in Original Containers
Detail-Document#: 300622
(subscription needed) http://www.prescribersletter.com
- Stivarga prescribing information.
http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf